Information for Clinicians: Approach to the Patient with Progressive Radioiodine-Refractory Thyroid Cancer—When to Use Systemic Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Information for Clinicians: Approach to the Patient with Progressive Radioiodine-Refractory Thyroid Cancer—When to Use Systemic Therapy

Published:2017-08 Issue:8 Volume:27 Page:987-993
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Cabanillas Maria E.¹,Terris David J.²,Sabra Mona M.³,for the American Thyroid Associatio

Affiliation:

1. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.

2. Department of Otolaryngology and Division of Endocrinology, Department of Medicine, Augusta University, Augusta, Georgia.

3. Endocrinology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill-Cornell College of Medicine, New York, New York.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2016.0578

Reference32 articles.

1. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

2. Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers With Radioiodine-Avid Distant Metastases

3. Relation between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid Cancer

4. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

5. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part III. Management of Advanced Differentiated Thyroid Cancers - Chapter 4. Systemic Therapy for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer 2024;International Journal of Thyroidology;2024-05-30

2. Clinical and Histopathological Risk Factors for Radioactive Iodine–Refractory Follicular and Oncocytic Thyroid Carcinoma;The Journal of Clinical Endocrinology & Metabolism;2024-02-13

3. Modern Diagnostic and Therapeutic Approaches in Thyroid Diseases: Theranostics and the Changing Role of Radioactive Isotopes;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024

4. Radioactive Iodine in Differentiated Thyroid Carcinoma: A Systematic AGREE II Clinical Practice Guideline Appraisal;Otolaryngology–Head and Neck Surgery;2023-09-11

5. Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in the progression of thyroid carcinoma;Cell Death Discovery;2022-03-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3